Based at MINATEC with a sales office in Boston, PX’Therapeutics develops recombinant proteins and monoclonal antibodies that are used in research, diagnostics, vaccines, and biotherapeutics.
Minatec Video Mini Player
PX’Therapeutics products are used by pharmaceutical companies, biotech firms, and university labs for a wide range of applications, including the treatment of infectious diseases, cancer, and allergies in both humans and animals. The company is leading a new trend toward the use of biotechnology to develop biotherapeutic proteins, a field that has traditionally not garnered as much interest from researchers, who have tended to focus on the main chemical families.
PX’Therapeutics generated €4 million of revenue in 2010—half of which came from outside France—and has 60 employees. It has two core businesses:
- The development of new products under R&D contracts
- The production of proteins and antibodies for clinical batches and niche markets.
In 2010 Promise Advanced Proteomics, a PX’Therapeutics subsidiary, set up a new protein quantification business using PSAQTM proprietary technology.
PX’Therapeutics currently has over 600 projects underway for 160 different customers.
For more information, visit www.px-therapeutics.com and www.promise-proteomics.com
